The Neurobiology of 5-Lipoxygenase

描述（由申请人提供）：阿尔茨海默病（AD）是一种慢性和复杂的神经退行性疾病，其导致认知功能的进行性丧失伴痴呆，并且无法治愈。衰老是发展AD的一个强有力的风险因素，并且失调的氧介导的事件以及炎症过程被认为是衰老和疾病发病机制之间的潜在生物学联系。5-脂氧合酶（5LO）是一种氧化脂肪酸的酶，从而合成炎症脂质介质（白三烯）和脂质过氧化产物（羟基过氧化物），这两者也是有效的氧化剂。这种酶在中枢神经系统（CNS）中广泛表达。然而，尽管一些间接证据表明它可能在神经退行性变中发挥作用，但5LO在CNS中的明确生物学作用尚未确定。我们最近发现，随着年龄的增长，5LO的表达水平在CNS中增加，特别是在海马中，并且与对照组相比，这种酶在AD脑中上调。我们还证明了5LO的基因切除导致野生型小鼠内源性A？水平降低，并且在AD样淀粉样变性小鼠模型Tg 2576小鼠中A？沉积显著减少。此外，在细胞培养系统中，5LO活化和药理学抑制分别导致A？形成增加和减少。总之，这些数据提供了强有力的支持的假设，这种酶的途径可以发挥作用，在AD的发病机制，并代表了一种新的治疗目标的疾病。目前的建议的主要目标是测试的假设，5LO激活的结果在生物活性脂质的形成，这反过来又调节代谢途径密切相关的AD神经病理学。阐明这种酶系统影响A？的产生和周转及其前体蛋白APP的代谢命运的分子和细胞机制是非常重要的，因为它可以建立与AD病理学发展相关的新途径，并成为新的治疗靶点。因此，如果成功，我们的研究结果将为未来研究提供重要线索，具体的5LO抑制剂作为预防或限制AD的演变和/或进展的新型治疗药物。

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a chronic and complex neurodegenerative disease that causes progressive loss of cognitive functions with dementia and for which there is no cure. Aging is a strong risk factor for developing AD, and dysregulated oxygen-mediated events as well as inflammatory processes are considered potential biological links between aging and the disease pathogenesis. 5-Lipoxygenases (5LO) is an enzyme that oxidizes fatty acids and thereby synthesizes inflammatory lipid mediators (leukotrienes), and lipid peroxidation products (hydroxyperoxides), both of which are also potent oxidants. This enzyme is widely expressed in the central nervous system (CNS). However, despite some circumstantial evidence suggesting that it may play a role in neurodegeneration, a definitive biological role for 5LO in the CNS has yet to be established. We recently showed that the expression levels of 5LO are increased in the CNS with aging particularly in the hippocampus, and that compared to controls this enzyme is upregulated in AD brains. We also demonstrated that genetic ablation of 5LO results in reduced endogenous A¿ levels in wild type mice, and significantly less A¿ deposits in the Tg2576 mice, a mouse model of AD-like amyloidosis. Further, in cell culture systems 5LO activation and pharmacologic inhibition results in increased and reduced A¿ formation, respectively. Together, these data provide strong support for the hypothesis that this enzymatic pathway could play a functional role in AD pathogenesis, and represent a novel therapeutic target for the disease. The main goal of the current proposal is to test the hypothesis that 5LO activation results in the formation of bioactive lipids, which in turn modulate metabolic pathways germane to the AD neuropathology. The elucidation of the molecular and cellular mechanisms whereby this enzyme system influences the production and turnover of A¿ and the metabolic fate of its precursor protein, APP, is extremely important since it could establish a novel pathway relevant to the development of AD pathology, and become a new therapeutic target. Thus, if successful, our findings will provide important clues for future studies with specific 5LO inhibitors as novel therapeutic agents for preventing or limiting the evolution and /or progression of AD.